This finding suggests that RNase1 and EGFR-CD3 bsAb collaborate to protect against breast cancer across different molecular subtypes 58, which may provide a rational strategy for immunocompetent patients with breast cancer by combining RNase1 with T-bsAb against specific antigens. Here, RNASE1 is linked to breast cancer.